PANACEA BIOTEC LTD. - 531349 - Statement Of Investor Complaints For The Quarter Ended June 2020
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Vinod GoelDesignation :- Company Secretary and Compliance Officer PANACEA BIOTEC LTD. - 531349 - Disclosure of Voting results of Postal Ballot (Regulation 44(3) of SEBI (LODR) Regulations, 2015)
Panacea Biotec Ltd has informed BSE regarding the details of Voting results of Postal Ballot, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. Kindly Click here PANACEA BIOTEC LTD. - 531349 - Details Of The Voting Results Of Postal Ballot Conducted Through Remote E - Voting Pursuant To Regulation 44(3) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
This is in continuation to our earlier letter dated June 17, 2020, intimating about the initiation of the process of postal ballot ('Postal Ballot') by the Company for seeking approval of the shareholders by way of special resolutions in terms of the Postal Ballot Notice dated June 16, 2020. In connection with the above, post receipt of the Scrutinizer Report, we would like to inform you that all the resolutions mentioned in the aforesaid Postal Ballot Notice have been passed by the shareholders with the requisite majority. Accordingly, pursuant to Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, details of voting results in the prescribed format along with the Scrutinizer's Report is enclosed herewith PANACEA BIOTEC LTD. - 531349 - Shareholding for the Period Ended June 30, 2020
Panacea Biotec Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2020. For more details, kindly Click here
Panacea Biotec aims to make 1 billion doses of COVID-19 vaccine candidate in 2022
The company said last month it would partner with US-based Refana Inc to make a potential COVID-19 vaccine, in a collaboration that expects to have over 40 million doses available early next year. PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Please find enclosed details of Shares dematerialized during June, 2020 PANACEA BIOTEC LTD. - 531349 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Dear Sir, We are enclosing herewith a certificate dated July 04, 2020, issued by Skyline Financial Services Private Limited, Registrar and Transfer Agent of the Company, confirming compliance under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2020. PANACEA BIOTEC LTD. - 531349 - Closure of Trading Window
Pursuant to the Company''s Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all the Designated Persons of the Company and Material Subsidiaries of the Company from July 01, 2020 till completion of 48 hours from the announcement to the Stock Exchanges of the Unaudited financial results of the Company for the quarter ended June 30, 2020. The date of meeting of the Board of Directors to approve the Unaudited financial results of the Company for the quarter ended June 30, 2020 will be informed in due course. PANACEA BIOTEC LTD. - 531349 - Audited Financial Results (Standalone And Consolidated) For The Quarter / Financial Year Ended March 31, 2020
We would like to inform you that the Board of Directors of the Company has, at its meeting held today, i.e. 29.06.2020, inter-alia, considered and approved the Audited Financial Results (Standalone and Consolidated) of the Company for the quarter/ financial year ended March 31, 2020. The same were also reviewed by the Audit Committee in its meeting held on June 29, 2020. A copy of the aforesaid Audited Financial Results (Standalone and Consolidated) along with Auditors' Report is enclosed herewith as Annexure-A. Further,we would like to confirm that the Auditors' Report on the Audited Financial Results (Standalone and Consolidated) for the financial Year ended March 31, 2020 is with unmodified opinion. Further, in view of losses, the Board of Directors has not recommended any dividend on the Preference as well as Equity Shares of the Company for the financial year ended March 31, 2020. The meeting of the Board of Directors commenced at 03:30 P.M. and concluded at 6.40 P.M.